All In Biotech

Drug Trial Radar · NCT07222215

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 297 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

297

Planned (sponsor's estimate)

Start

Jan 16, 2026

Primary completion

Dec 1, 2029

Study completion Oct 1, 2030

Sponsor

Lead sponsor
Kristina A. FanucciAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Stemline Therapeutics, Inc.; Johns Hopkins University; Translational Breast Cancer Research Consortium; Menarini Group; Gateway for Cancer Research; Terri Brodeur Breast Cancer Foundation
First posted
Oct 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medication in the class of therapy called CDK 4/6 inhibitors, including palbociclib, ribociclib, or abemaciclb. The names of the study drugs involved in this study are: * Elacestrant (a type of selective estrogen receptor degrader) * Capecitabine (a type of fluoropyrimidine antimetabolite)

Conditions

  • Estrogen-receptor-positive Breast Cancer
  • Metastatic Breast Cancer
  • Breast Cancer
  • Hormone Receptor Positive Breast Cancer
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • HER2- Breast Cancer
  • ESR1 Gene Mutation
  • ER Wildtype
  • Breast Neoplasms

Interventions

  • CapecitabineDrug

    A fluoropyrimidine carbamate, tablet taken orally, per standard of care.

  • ElacestrantDrug

    A selective estrogen receptor degrader, tablet taken orally, per standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) in ESR1 mutant populationTime frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles.
  2. Progression Free Survival (PFS) in intention to treat (ITT) populationTime frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.